Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis

Exclusion Criteria

• •Female subjects of childbearing potential who are pregnant, attempting to conceive, or nursing an infant.
• •Subjects who have received PUVA or UVB light therapy or systemic antipsoriatic therapy within 4 weeks of study treatment (two weeks for methotrexate).
• •Subjects who have received topical antipsoriatic therapy (including corticosteroids, tar, anthralin, or Vitamin D analogs) to the study plaque areas within 2 weeks of study treatment.
• •Subjects who have received any photosensitizing or phototoxic drug within 4 weeks of study treatment.
• •Subjects who have received any approved biologic drug therapy for psoriasis within 3 months or 5 half-lives of study treatment.
• •Subjects who have participated in a clinical research study within 4 weeks of study treatment.
• •Subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.
• •Subjects with clinical conditions that, in the opinion of the Principal Investigator, may pose a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.